公司資料
Kyverna Therapeutics 股價、新聞與催化劑
- 股票代碼:
- KYTX
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
8.95 USD (+9.55%)
收盤價
最後更新: 2026年8月17日
480M USD
市值
股價為何變動
As of Aug 17, 2026, KYTX closed up 9.55% at $8.95. No new same-company headline was identified in the current news window.
公司概覽
Autoimmune CAR T Company
Kyverna Therapeutics develops autologous CD19-directed CAR T-cell therapy for B-cell-driven autoimmune diseases.
Miv-cel
Mivocabtagene autoleucel, or miv-cel, is a fully human CAR T therapy designed to produce deep B-cell depletion after a single administration.
Stiff Person Syndrome
The pivotal KYSA-8 study supports the first planned BLA for an autoimmune CAR T therapy in stiff person syndrome.
Broader Autoimmune Development
Kyverna is also advancing miv-cel in generalized myasthenia gravis and other autoimmune disorders.
未來催化劑
- Completion of the rolling miv-cel BLA submission in stiff person syndrome is expected in the fourth quarter of 2026.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。